Retrospectively Analyzed The Effectiveness & Safety Of Raltitrexed For The Tace Of Malignant Liver Tumors

ObjectiveCompare the safety & effectiveness of raltitrexed and fluorouracil for the TACE of malignant liver tumors.MethodsMake a retrospective analysis on clinic data of the 42 patients with malignant liver tumors that was treatmented by TACE in the department of hepatobiliary surgery of our hospital from September 2013 to September 2015. They were divided into group A and group B according to the chemotherapy regimens(16 raltitrexed and 26 fluorouracil).Patients were evaluated with modified response evaluation criterria in solid tumor(mRECIST)every 1-3 months after TACE. Observe two groups of patients with overall response rate(ORR), disease control rate(DCR), progression-free survival(PFS), median survival time and incidence of adverse events. Overall survival was the primary endpoint. The follow-up deadline was March 1, 2016.No statistically significant differences were observed in overall response rate(12.5% and 11.5%; P= 0.926),disease control rate(81.3% and 80.8%; P = 0.969),median progression-free survival(10 and 9 months; P=0.686), and median survival time(13 and 10 months; P=0.630) for group A and group B, respectively. Grades III and IV transaminase elevation(P= 0.023) was more common with the raltitrexed regimen. Comprehensive analysis grades IV hematologic adverse events, it was more common with the fluorouracil regimen(P= 0.016).ConclusionTo the patients with TACE of malignant liver tumors,the raltitrexed regimen alternative the fluorouracil regimen was an effective and safe palliative treatment.